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Abstract
Background:  The aim of the present study was to assess the occurrence of glutamic acid
decarboxylase autoantibodies (GADA) and insulinoma antigen 2 autoantibodies (IA2A) among
patients of African origin in Dar es Salaam, Tanzania and to compare the occurrence of
autoimmune mediated Type 1 diabetes with findings previously reported from the same place and
from other African diabetic populations.
Methods: Two hundred and forty five patients from the diabetic clinic at Muhimbili Hospital were
recruited for a cross sectional study. Patients were clinically classified into groups with Type 1
(T1D) and Type 2 diabetes (T2D); there were 94 patients with T1D and 151 with T2D.
Autoantibodies for GAD and IA2 were measured with an assay based on radioligand binding.
Fasting and random blood glucose, HbA1c, and C-peptide levels were also determined.
Results: Of the patients with T1D, 28 (29.8%) were GADA positive and 20 (21.3%) were IA2A
positive. The overall occurrence of any autoantibody was 42.6%. The GAD and IA2 autoantibodies
were detected more frequently among patients with T1D than among patients with T2D (P <
0.001). A higher autoantibody prevalence was observed with combined GADA and IA2A
measurements compared to individual autoantibody measurements; 40 (42.6%) patients with T1D
versus 11 (7.3%) with T2D had at least one positive autoantibody titer. There was no correlation
between duration of disease and detection of autoantibodies in patients with T1D. There was a
strong association with family history of diabetes among the autoantibody positive versus
autoantibody negative patients with T1D (p < 0.01).
Conclusion: The prevalence of GAD and IA2 autoantibodies among African patients with T1D in
Dar es Salaam was the same as that reported previously for South Africa and Ethiopia. It was much
higher than the prevalence of islet cell autoantibodies (ICA) reported from the same clinic about
15 years ago. For unknown reasons the prevalence of pancreatic related autoantibodies in this
African population is lower than the prevalence found among Caucasian populations.
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Background
For the past 30 years Type 1 diabetes mellitus (T1D) has
been regarded as an autoimmune disease which leads to
pancreatic  β-cell destruction and absolute insulin defi-
ciency [1]. However, evidence supporting the autoim-
mune component of T1D is inconsistent. It is unclear
whether this is due to an inconsistency in techniques or an
inconsistency arising from an underlying genetic variabil-
ity in different populations. Studies in Caucasian popula-
tions have revealed an 80–90% occurrence of
autoantibodies in patients newly diagnosed with T1D
[2,3]. Recent reports from Asia have demonstrated an
83.3% – 90% occurrence of glutamic acid decarboxylase
autoantibodies (GADA) in Japanese patients with T1D
[4,5]. However earlier studies in the 1980's reported an
occurrence as low as 7% of islet cell autoantibodies (ICA)
in Japanese patients with T1D [6] and around a 40%
occurrence in a mixed Asian population with T1D in Sin-
gapore [7,8].
There are relatively few studies regarding autoantibody
prevalence in sub-Saharan Africa. During the 1980's scien-
tific findings indicated a low occurrence of ICA ranging
from 7–9% in patients with T1D from Nigeria and Tanza-
nia [9,10]. On the other hand, studies during the same
period reported an occurrence of ICA of 36% in patients
with T1D of African origin from South Africa [11], and an
occurrence of islet cell surface autoantibodies (ICSA) of
43% in patients from Ethiopia that required insulin to
control diabetes [12]. A study from South Africa in 2002
[13] using a newer, simpler, and more precise method for
detecting autoantibodies (by radioimmunoassay) identi-
fied GAD autoantibodies in 44% of patients with T1D and
2.5% of African patients with Type 2 diabetes (T2D). Stud-
ies in African Americans with newly diagnosed Type 1 dia-
betes also report a low ICA prevalence [14,15] compared
with that reported in Caucasian populations with T1D.
The studies from South Africa and Ethiopia suggest that
autoimmunity plays a role in the pathogenesis of Type 1
diabetes in African patients as well. Because populations
with Type 1 diabetes in Asia and Africa exhibit less than
50% prevalence of diabetes related autoantibodies, the
American diabetes association (ADA) [16] and the World
Health Organization [17] have sub-classified Type 1 dia-
betes into Types 1a and 1b, where Type 1a is autoimmune
mediated, and Type 1b is non-autoimmune mediated, or
idiopathic Type 1. There appear to be no significant clini-
cal differences between patients with or without circulat-
ing autoantibodies [9,11,13]
Glutamic acid decarboxylase (GAD) and a protein tyro-
sine phosphatase-like molecule known as insulinoma
antigen 2 (IA2) have been widely used as markers to
describe the pathogenesis and the clinical course of Type
1 diabetes, though the nature of their involvement in the
disease remains uncertain [3,18]. In Caucasians, about
10–15% of patients clinically diagnosed with T2D also
have islet cell autoantibodies, especially GADA [19]. Cur-
rently, radioimmunoassays for GADA and IA2A are com-
monly used for assessing pancreatic islet cell
autoantibodies. In the earlier study from Dar es Salaam,
the occurrence of autoantibodies was not different in the
IDDM and NIDDM patients [9]. This raises the question
of whether some of the IDDM individuals were misclassi-
fied.
The aim of the present study was to assess the occurrence
of autoantibodies in patients with Type 1 and Type 2 dia-
betes in Dar es Salaam using current techniques with
GADA and IA2A and to compare these results with earlier
findings from the same diabetic clinic, and also with the
prevalence of autoantibodies reported in other studies
from African countries.
Methods
Study Design and Patients
Two hundred and seventy one patients of African origin
were enrolled between July 2003 and March 2004 in this
cross-sectional study. All patients regularly attended the
Diabetes Clinic of the Muhimbili National Hospital in
Dar es Salaam. The Clinic does not differ in attendance
from the other three municipal diabetes clinics in Dar es
Salaam, as most of the patients attend both their munici-
pal clinic and the Muhimbili Clinic. We therefore believe
that patients attending the Clinic do not differ substan-
tially from those attending the other clinics with regard to
the type of diabetes, age, duration of disease, or sex distri-
bution. The study was performed with the patients' writ-
ten informed consent, according to the amended
Declaration of Helsinki., and approved by the Scientific
and Publication Committee of Muhimbili University Col-
lege of Health Sciences and the Regional Committee for
Medical Research Ethics of Western Norway.
Data collection
A structured interview schedule was used to collect demo-
graphic information. Sociodemographic data included
age at diagnosis, age at inclusion, gender, family history of
diabetes, drinking and smoking habits, and the duration
of diabetes. In cases of patient uncertainty the duration
was calculated from the documented date of diagnosis.
Other information was obtained from the patients' files,
including the mode of presentation, type of treatment,
and course of the disease.
Clinical assessment
All patients were given a thorough physical examination.
Body weight was measured to the nearest 0.5 kg and
height to the nearest 0.5 cm. Body mass index (BMI) was
calculated as weight (kg)/height (m2). Waist and hip cir-Journal of Autoimmune Diseases 2007, 4:4 http://www.jautoimdis.com/content/4/1/4
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cumference was measured and the waist-to-hip ratio cal-
culated (WHR). Blood samples were collected (see
below).
Classification of diabetes
Patients were classified as Type 1 or Type 2 according to
the clinical criteria recommended in the 1997 World
Health Organisation [17] report. Classifications were
based on age at diagnosis, mode of onset (acute versus
insidious presentation), duration of disease, current treat-
ment, BMI, waist-to-hip ratio, blood pressure, random or
fasting glucose, HbA1c and urine ketones. A classification
of Type 1 diabetes was defined by the following criteria:
onset in patients aged 30 years or less, presentation of
acute classical symptoms, and that required insulin ther-
apy to control hyperglycaemia,. A classification of Type 1
diabetes was also designated to patients older than 30
years that required insulin treatment, lacked metabolic
control, and were determined to be underweight. A classi-
fication of Type 2 diabetes was designated to patients who
were older than 30 years at diagnosis and did not need
insulin for metabolic control. A Type 2 classification was
also designated to patients younger than 30 years who
were obese and had diabetes for a long duration without
requiring insulin treatment. Patients that did not clearly
exhibit the clinical features of either Type were classified
as undetermined and excluded from the present analysis.
Blood sample collection and storage
A morning sample of 6 ml of venous blood was drawn
from each subject and centrifuged within 2 hours of col-
lection. The sera were frozen at -80°C and transported to
Bergen in a dry ice-filled container that maintained the
temperature between -50°C to -70°C. Samples reached
their destination within 24 hours and were stored at -
80°C.
Blood glucose and HbA1c measurements
Capillary blood glucose was measured using a HemoCue
AB glucose analyzer (Angelholm, Sweden). The accuracy
range was 0–22 mmol/l; all readings above 22 mmol/l
were displayed as ≥22 mmol/l.
HbA1c was measured immunochemically using a DCA
2000®+ (Bayer Corporation) [20]. The instrument was
standardized against the DCCT method and was certified
in 1996 [21].
Autoantibody measurements
Radioligand assays were used for detecting both GADA
and IA2A (CentAK® anti-GAD; CentAK® anti-IA2; manu-
factured by Medipan Diagnostics, Selchow, Germany). A
highly purified human recombinant GADA-65 was
labelled with 125-Iodine (125I). The tracer was added in
excess to the samples and bound the GAD-65 autoanti-
bodies. Likewise, a highly purified human recombinant
IA2A (intracellular sample of IA2A) was labelled with 125I.
The tracer was added in excess to the samples and bound
the IA2 autoantibodies. All samples were run in duplicate
and results were expressed in arbitrary units/ml. The radi-
oactive signals (cpm) were measured with the Wallac
1470 Wizard® Gamma counter machine (Wallac Oy, Fin-
land). Samples were analyzed within 2 months of receipt.
The GADA and IA2A assays were evaluated in the first
WHO Assay Proficiency Evaluation (Lab assay number
145) of the Diabetes Antibody Standardization Program
(DASP) [22]. In this study the GADA assay had an
adjusted median sensitivity of 80% and specificity of
90%, while the IA2A assay had a median sensitivity of
58% and specificity of 100%. In addition, the CentAK®
anti-GAD test was examined in the 4th GADA Proficiency
Study of the University of Louisiana (New Orleans, USA)
in 1999, and displayed 100% specificity and sensitivity.
The CentAK® anti-IA2A was also examined in the 3rd IA2
antibody Proficiency Study of the University of Louisiana,
New Orleans, USA, and displayed 100% sensitivity and
specificity. Furthermore, in a German comparative study
of commercially available immunoradioactive assays, the
Medipan CentAK® GADA assays displayed 85% sensitivity
and 100% specificity in newly diagnosed patients with
T1D [23-26]. According to the respective instruction man-
uals, assay sensitivities (lower detection limits, corre-
sponding to the 10% intra-assay and to the 20% inter-
assay coefficients of variation in the precision profiles in
the lower concentrations range) were 0.7 U/ml for the IA2
assay and 0.6 U/ml for the GADA assay. The reference val-
ues (normal ≤ 0.75 U/ml for the IA2 assay and <0.9 for the
GADA assay) have been established in European popula-
tions, and were used in the studies mentioned above [23-
26]. Mean coefficients of variance over the past year for
control solutions with high and low titres respectively
were 7.03% and 6.09% in our laboratory. To our knowl-
edge no studies using CentAK® antibody assays have been
performed in ethnic groups other than Caucasians.
C-peptide assays
The C-peptide assays were performed using the IMMU-
LITE 2000 Automated Chemiluminescent Immunoassay
Analyzer (Diagnostic Products Corporation kits of EURO/
DPC Ltd., Flanders, NJ, USA). All samples were assayed in
duplicate. The minimum detection limit was 0.003 nmol/
l, with intra-assay variability of <9%. C-peptide concentra-
tions were categorized in two groups: C-peptide negative
and C-peptide positive. C-peptide-negative levels were
those with either fasting C-peptide levels <0.3 nmol/l or
glucose-stimulated [plasma glucose ≥10 mmol/l] C-pep-
tide levels <0.6 nmol/l. The C-peptide-positive levels were
those with fasting C-peptide levels ≥0.3 nmol/l or glucose-
stimulated C-peptide levels ≥0.6 nmol/l.Journal of Autoimmune Diseases 2007, 4:4 http://www.jautoimdis.com/content/4/1/4
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Statistical analysis
Distribution within groups was tested for skewness and
distributions between groups was tested for statistically
significant differences of standard deviations. Parametric
and nonparametric tests were then used as appropriate.
For continuous variables, either the unpaired t-test or the
Mann-Whitney test (parametric and nonparametric tests)
was performed. Differences between proportions were
assessed by Fisher's exact test or by the chi-square test.
The correlation between disease duration and the occur-
rence of autoantibodies was determined with the Spear-
man nonparametric correlation test. Data were analyzed
using SPSS version 14 for Windows. A p-value <0.05 was
considered statistically significant.
Results
Sociodemographic characteristics of the study population
Two hundred and seventy one patients were enrolled;
54.3% were women. Eight patients did not complete the
study and were excluded. Fourteen patients had presenta-
tions that could not clearly be classified as type 1 or type
2 diabetes, and they were excluded. Four patients who did
not undergo autoantibody tests were also excluded. The
final study population thus consisted of 151 patients with
T2D and 94 patients with T1D. The sex distribution in the
two groups was not different. The median overall dura-
tion of diabetes was 3.6 years (range 0–25). Patients with
T2D had significantly longer median durations of diabe-
tes than patients with T1D (4 versus 3 years, p < 0.001).
Patients with T2D were significantly older and had higher
BMI and WHR. In addition, a significantly (p < 0.001)
higher proportion of patients with T2D had normal C-
peptide levels compared to patients with T1D. Patients
with T1D had a higher median HbA1c (13.7%) compared
to that observed in patients with T2D (9.6%) (p < 0.001).
(Table 1)
GAD and IA2 autoantibody positivity
Autoantibodies were determined in 245 patients: 94
(38.4%) with T1D and 151 (61.6%) with T2D. Of the 245
patients, 36 (14.7%) had positive GADA levels (≥1 U/ml):
28 (78%) with T1D, and 8 (22%) with T2D. Twenty-three
of the 245 (9.4%) patients had positive IA2A levels (≥1 U/
ml): 20 (87%) with T1D and 3 (13%) with T2D. In the
patients with T1D the frequencies of positive GAD (78%)
and IA2 (87%) autoantibodies were not significantly dif-
ferent (p > 0.05). However, the detection of GAD and IA2
antibodies was significantly more frequent among
patients with T1D than in patients with T2D (p < 0.0001).
Forty (43%) patients with T1D versus 11 (7.3%) patients
with T2D had at least one autoantibody positive titer, and
8 (9%) patients with T1D versus no patients with T2D
tested positive for both GADA and IA2A (Table 2). The
detection of autoantibodies was not significantly influ-
enced by gender in either class of diabetes.
During the 1–2 year interval of the disease, patients with
T1D exhibited the highest {n = 9, (50%)} frequency of
detection of any autoantibodies; thereafter the frequency
dropped slightly. However, there was no inverse correla-
tion between the duration of disease and the frequency of
detection of autoantibodies in the patients with T1D (Fig-
ure 1). In patients with T2D, the frequency of detection of
any autoantibodies was lowest during the 1–2 year inter-
val of the disease, and increased thereafter.
HbA1c, BMI, WHR, age at diagnosis, duration of disease
and treatment with insulin were not significantly different
between patients with T1D that were autoantibody posi-
tive or autoantibody negative. There was, however, a sig-
nificantly higher proportion of patients with a family
history of diabetes among those who were autoantibody
positive compared with those who were autoantibody
negative (p < 0.01, Table 3).
Table 1: Basic socio-demographic and biochemical characteristics of the patients with diabetes
Variables Type 1 Type 2
Total n (%) 94 (38.4) 151 (61.6)
Female n (%)  50 (53.2) 85 (56.2)
Age at diagnosis [median (min-max)] years 17 (4–60) 48 (20–79) ***
Diabetes duration [median (min-max)]years 3 (0–17) 4 (0–25)***
Family history of diabetes n (%) 42 (44.7) 67(45)
BMI [mean ± SD] kg/m2 19.5 ± 4.4 27.8 ± 4.7 ***
Waist-to-hip ratio  [mean ± SD] 0.87 ± (0.07 0.94 ± 0.1 ***
HbA1c[median (min-max)]% 13.7 (6->14) 9.6 (5.2->14)***
Normal C-peptide levels# n (%) 7 (7.6) 96 (63.6) ***
*P < 0.05; **P < 0.01; ***P < 0.001.
 Fisher's Exact Test  Mann-Whitney,  Unpaired t- test
#Normal C-peptide levels: fasting >0.3 nmol/l; random >0.6 nmol/l.Journal of Autoimmune Diseases 2007, 4:4 http://www.jautoimdis.com/content/4/1/4
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Discussion
This study investigated the prevalence of GADA and IA2A
in patients of African origin with diabetes in Dar es
Salaam, Tanzania. The main finding from this study was a
significantly higher prevalence of detecting any autoanti-
body (42.6%) among patients with T1D compared to the
prevalence (7.3%) among patients with T2D. Eight
(8.5%) patients with T1D and no patients with T2D had
both GAD and IA2 autoantibodies. Our findings suggest
that around 50% of patients with T1D have diabetes due
to an autoimmune process. These findings contrast with
those reported 15 years ago by McLarty et al from the same
clinic; they found that the prevalence of ICA positive
patients was not different among insulin-dependent and
non-insulin-dependent patients [9]. They concluded that
islet cell autoantibodies were not correlated to insulin-
dependent diabetes. Another study from Nigeria used
indirect immunofluorescence to measure islet cell autoan-
tibodies; a method that is cumbersome and difficult to
standardize [18]. They demonstrated a much lower fre-
quency of autoantibodies than that reported here in
patients with T1D [10]. However, our study is not directly
comparable to those studies due to differences in the
assays used, differences in sensitivity levels, and differ-
ences in the way patients were classified. On the other
hand our findings are in accordance with the results from
Ethiopian and South African studies [11-13]. Compared
to other non-Caucasian ethnic populations with T1D, we
found similar autoantibody prevalences. For instance, in
a study from Saudi Arabia, patients with T1D were 54%
positive for GADA and 27% positive for IA2A [27]. Addi-
tionally, in a study from Taiwan patients with T1D were
47% positive for GADA and 23.6% positive for IA2A [28].
To our knowledge, this is the first study to evaluate com-
bined GAD and IA2 autoantibody measurements among
African patients with diabetes. As reported in other stud-
ies, we found that measuring more than one type of dia-
betes-related autoantibody increased the likelihood of
detecting Type 1 diabetes autoimmunity in a population
[29-32].
Our findings suggest that around 50% of patients with
T1D have the autoimmune mediated form of the disease
(Type 1a diabetes, Figure 1). These results support the
notion raised in previous reports from African studies
regarding the existence of unknown disease mechanisms
that operate in the other half the African population with
T1D. We may, however, speculate that future studies in
African populations are likely to uncover novel autoanti-
bodies against beta cell components, demonstrating that
the pathogenesis of Type 1b diabetes is autoimmune
mediated as well.                 
Significantly more patients with T1D that were autoanti-
body positive had a positive family history of diabetes
compared with those who were autoantibody negative;
this is in accordance with the well-known notion that
autoimmune diabetes has a genetic basis [33-35]. Some
Prevalence of any antibody in patients with different dura- tions of diabetes (time intervals since diagnosis) Figure 1
Prevalence of any antibody in patients with different 
durations of diabetes (time intervals since diagnosis). 
In patients with T1D, the prevalence of any antibody was 
highest {n = 9, (50%)} in the 1–2 year interval of the disease, 
and thereafter dropped slightly. In patients with T2D the 
prevalence was lowest in the 1–2 year interval of the disease, 
and slightly increased thereafter. There was no inverse cor-
relation between duration of disease and autoantibodies in 
the patients with T1D.
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Table 2: Prevalence of GADA and IA-2A in Type 1 and Type 2 diabetes
Antibody status Type 1 Diabetes N = 94 
n(%)
Type 2 Diabetes N = 151
n(%)
Both GADA- and IA-2A-positive 8(8.5) 0
GADA-positive only 20 (21.3) 8 (5.3)
IA-2A-positive only 12 (12.8) 3 (2)
Any antibody positive 40 (42.6) 11 (7.3)
Antibody negative 54 (57.4) 140 (92.7)Journal of Autoimmune Diseases 2007, 4:4 http://www.jautoimdis.com/content/4/1/4
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studies have shown disappearance of GADA and IA2A
with time [36], while others have shown an increase of
autoantibodies with time, up to a point, and still others
have shown seroconversion to autoantibody positivity
within the first few years of the disease after being negative
at diagnosis [31]. About 75% of our patients had the dis-
ease for less than 4 years. Our results did not indicate any
reduction in autoantibodies with time but rather showed
a rise within the second year of the disease. Therefore it is
unlikely that the low prevalence of autoantibody-positive
patients in our study, compared with findings among
Caucasians, might be explained by the disappearance of
positive autoantibody titers as time passes.
Conclusion
The prevalence of GADA and IA2 autoantibodies among
African patients with T1D in Dar es Salaam was much
higher than the prevalence of ICA previously reported
from the same clinic about 15 years ago. However, the
current findings are in accordance with reports from
South Africa and Ethiopia. There is a strong association
with family history among the autoantibody positive ver-
sus autoantibody negative patients with T1D. The preva-
lence of pancreatic related autoantibodies in this African
population is considerably lower than prevalences found
among Caucasians.
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